NK042 cell injection for advanced solid tumors
Official title: An Open-Label, Single-Arm, Multicenter Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of NK042 Cell Injection (Universal NKR+NK) in Advanced Solid Tumors
Run by Shanghai NK Cell Technology Co., LTD · NCT06773091 · Data updated 2026-11-12
This study is testing a new cell injection called NK042 to see if it can safely help people with advanced solid tumors.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 76 (estimated) |
| Sponsor | Shanghai NK Cell Technology Co., LTD Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | February 7, 2025 |
| Main results expected | December 2026 |
| Study ends | June 2027 |
| Registry record updated | April 6, 2026 |
| Trial ID | NCT06773091 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 70 with histologically confirmed advanced solid tumors that are not amenable to surgical resection and have no standard treatment options available.
✕Probably not a fit
Patients who have recently undergone other anti-tumor treatments or are currently participating in other clinical trials may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors. The study consists of two phases: Phase Ia, which involves dose-escalation with both single and multiple doses of NK042, and Phase Ib, which focuses on expanding cohorts for solid tumor indications that showed preliminary efficacy in Phase Ia. The study aims to assess how well NK042 can be tolerated and its potential effectiveness in treating these tumors.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors who have limited or no standard treatment options.
How similar studies have gone: While this approach is novel, similar studies using CAR-NK cell therapies have shown promise in early-phase trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntary signing of a written informed consent form. 2. Age between 18 and 70 years. 3. Histologically or cytologically confirmed locally advanced or metastatic solid tumor patients who are not amenable to surgical resection, with no standard treatment options, or who have relapsed or progressed after standard treatment, or are resistant or intolerant to standard treatment. 4. At least one assessable tumor lesion according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. 6. Expected survival ≥12 weeks. 7. Must have adequate bone marrow, liver, and renal function. Exclusion Criteria: 1. Insufficient washout period for prior anti-tumor treatments before the first dose, including chemotherapy, targeted therapy, antibody therapy, and radiotherapy. 2. Participation in another clinical trial and use of investigational drugs within 28 days before the first dose. 3. Requirement for anticoagulation therapy. 4. Symptomatic brain parenchymal metastases with less than 4 weeks of stability after treatment. 5. Active pulmonary diseases, including but not limited to interstitial lung disease, pneumonitis. 6. Uncontrolled active infections. 7. Uncontrollable massive pleural effusion, ascites, or pericardial effusion. 8. Previous receipt of other cellular therapies. 9. Planned concurrent participation in other anti-tumor treatments during the study. 10. Pregnant or breastfeeding women.
Where it's running
-
Peking University Cancer Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Yongling Fu
- Email: yongling.fu@nk-celltech.com
- Phone: +0086 02150888199
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.